Maintains healthy lipid metabolism and oxidative status*
Additional considerations include: Hypoglycemia : Low risk as monotherapy but increased when combined with insulin or sulfonylureas
Discuss any history of thyroid problems, pancreatitis, kidney issues, or gallbladder disease
Both oral and injectable forms of semaglutide have been associated with gastrointestinal side effects, although these side effects are generally short-lived and mild-to-moderate in severity
Wegovy tablets and injections are FDA-approved in adults for: weight loss and weight management in adults with obesity or adults who are overweight and have a weight-related medical problem (e.g., blood pressure, type 2 diabetes, or high cholesterol) reducing major cardiovascular event risks (such as heart attack, stroke, or death) in adults with established CV disease and either obesity or overweight Wegovy injection is also FDA-approved for: weight loss and weight management patients with obesity who are 12 years and older non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), this is an accelerated approval